Carbon-14 BIA 28-6156 ( DrugBank: BIA, Carbon )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
6. Parkinson disease
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05220072 (ClinicalTrials.gov) | August 28, 2021 | 18/11/2021 | Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156 | An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of Carbon-14 BIA 28-6156 in Healthy Male Subjects | Parkinson Disease | Drug: Carbon-14 BIA 28-6156 | Bial R&D Investments, S.A. | NULL | Completed | 30 Years | 65 Years | Male | 6 | Phase 1 | United Kingdom |